Verve
PublicLast Round
M&A
Jun 17, 2025
Est. Valuation
$1.3B
Total Funding Raised
$1.95B
Company Overview
Verve Therapeutics (NAS: VERV) is a biotechnology company focused on developing innovative gene editing therapies to address cardiovascular disease through single-course treatments targeting key genetic factors.
Sector
Healthcare
AI Layer
Non-AI
Keywords
single-course gene editing medicinein vivo base editing therapygene editing for cardiovascular diseaseatherosclerotic cardiovascular disease (ASCVD) treatmentlipid nanoparticle (LNP) delivery for gene editingPCSK9 gene inactivation therapygenetic hypercholesterolemia therapyliver-targeted gene editingpermanent cholesterol lowering treatmentANGPTL3 gene targeting therapybiotech co-development partnership modelclinical-stage gene editing company
Verve Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Verve Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Jun 17, 2025 | ||||
| Follow-on Offering | Dec 1, 2023 | ||||
| Private Placement | Dec 1, 2023 | ||||
| IPO Announced | Jun 17, 2021 | ||||
| Series B | Jan 19, 2021 | ||||
Series A Extension | Jun 11, 2020 |
Verve Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B |
| Jefferies | IPO |
| Janus Henderson Group | Series B |
| RA Capital Management | Series B |
| GV | Series B, Series A Extension, Series A |
| Guggenheim Securities | IPO |
| F-Prime Capital | Series A Extension, Series A |
Verve Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersCambridge, Massachusetts
Employee Range175
Year Founded2018
Last FundingJun 17, 2025